Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
Najmul Hasan Forhad, Medical Laboratory Technician at Doctors Without Borders, shared on LinkedIn:
”Topic : Immunohematology and Hemostasis
von Willebrand factor (vWF) concentrates is essential in both clinical practice and laboratory medicine, especially when managing patients with von Willebrand disease (vWD) and certain cases of hemophilia A.
Several therapeutic products are commonly used in replacement therapy, including Alphanate, Humate P, Wilate, and recombinant von Willebrand factor preparations.
Alphanate and Humate P are plasma-derived concentrates containing both vWF and factor VIII, providing effective hemostatic support in patients with bleeding disorders.
Humate P is particularly recognized for its predictable vWF:FVIII ratio and is widely used in surgical prophylaxis and severe bleeding management.
Wilate is another plasma-derived product that is highly purified and formulated to closely resemble the physiologic balance between vWF and factor VIII.
It is commonly used for both acute treatment and prophylactic therapy.
Recombinant von Willebrand factor products represent an important advancement in transfusion medicine and hematology.
Because they are not plasma-derived, they minimize the risk of blood-borne pathogen transmission and offer a more targeted therapeutic approach.
From an educational and examination perspective, understanding the differences between plasma-derived and recombinant products, their clinical indications, and their role in different subtypes of vWD remains highly important for laboratory professionals and healthcare practitioners.
Clinical laboratory science continues to play a critical role in bridging diagnostic hematology with evidence-based patient management.”
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders